Departure. Clinical Miss. Billion: Should You Bet on Pfizer?
Pfizer faces a trio of headwinds: a CFO departure, a clinical miss, and a billion-dollar bet on Seagen. This article ...
Compare how robo advisor fees stack up against potential returns to help you decide if automation fits your investing plan. This intro explains the core cost-benefit idea in plain terms.
22,067 articlesPfizer faces a trio of headwinds: a CFO departure, a clinical miss, and a billion-dollar bet on Seagen. This article ...
NVIDIA’s market value dips below the $5 trillion threshold as traders reassess AI demand and supply dynamics. Analyst...
Public feuds grab headlines and dollars alike. This article uses the Katie Price reignites Victoria moment to show pr...
David Senra has turned down every acquisition proposal for his solo-operated podcast, choosing independence and creat...
A bold claim from a veteran tech analyst puts SpaceX at the center of an AI-enabled future. This guide breaks down wh...
A billionaire places a bold personal bet on a private space company. This article breaks down what that move means fo...
Starting with little cash and limited credit? Discover actionable tactics to find fund your first real estate deal, f...
Berkshire Hathaway disclosed a $351.7 million investment in The New York Times, marking a surprising return to tradit...
A high-stakes media merger is drawing political attention and investor caution. Eight Senate Democrats are pressing D...
Palantir is navigating a mix of headwinds and catalysts as 2026 unfolds. Here are three grounded predictions palantir...
Nvidia’s CEO just handed investors a fresh signal about AI demand and Nvidia’s path forward. This guide breaks down t...
OpenAI secures a historic $110 billion funding round from Amazon, Nvidia and SoftBank, driving its valuation to about...